期刊
PROSTATE
卷 69, 期 14, 页码 1507-1520出版社
WILEY
DOI: 10.1002/pros.20997
关键词
castration-resistant prostate cancer; basal; 8(q) copy number gain; Cancer cell lines
资金
- Bob Champion Cancer Trust
- Prostate Cancer Research Foundation
- Cancer Research UK
- Department of Health.
- MRC [G0501019] Funding Source: UKRI
- Medical Research Council [G0501019] Funding Source: researchfish
- National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish
INTRODUCTION. New in vitro models of castration-resistant prostate cancer (CRPC) are urgently required. METHODS. Trans-rectal needle biopsies (TRBP) of the prostate were performed for research purposes on progressing CRPC patients who had not received prior treatment to the prostate. Biopsies were immediately digested with collagenase and plated onto collagen-coated flasks with a feeder layer of 3T6 cells and cultured in cytokine-supplemented keratinocyte serum-free medium. RESULTS. Biopsies from 25 patients were collected and one of these, following an initial period of crisis, spontaneously immortalized. A series of cell lines called Bob were then established from a clone that survived CD133-selection followed by 4 weeks under adhesion-independent conditions in methylcellulose. Gains and losses previously described in clinical prostate tumors, most notably loss of 8(p) and gain of 8(q), were identified on comparative genomic hybridization and long-term growth in culture, survival in methylcellulose and invasion through matrigel confirmed the malignant phenotype of Bob. Furthermore, Bob expressed high levels of p53 and markers of early differentiation, including K8, prostatic acid phosphatase and prostate stem cell antigen. There was, however, no in vivo growth and ERG and ETV1 were not rearranged. Growth in serum permitted some differentiation. CONCLUSION. This is the first spontaneously immortalized prostate cancer cell line to be established from a TRBP of a patient with CRPC. Bob is a novel pre-clinical model for functional studies in CRPC and especially for studying the CRPC basal phenotype. Prostate 69: 1507-1520, 2009. (C) 2009 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据